Subscribe to Cardiovascular
View Sample

FREE Email Newsletter

Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts

February 23, 2011 6:33 am | by Bio-Medicine.Org | News | Comments

WOONSOCKET, R.I., Feb. 23, 2011 /- Xenogenics Corporation ("Xenogenics"), a majority owned subsidiary of MultiCell Technologies, Inc. (OTC Bulletin Board MCET), is pleased to announce it has retained the Emmes Group to assist with the development and execution of its capital formation...

Abaxis, Inc. to Present at RBC Capital Markets' Healthcare Conference

February 23, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

UNION CITY, Calif., Feb. 23, 2011 /- Abaxis, Inc. (Nasdaq: ABAX ), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer, will present at the RBC Capital Markets' Healthcare Conference on...

Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study

February 23, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

CARLSBAD, Calif., Feb. 23, 2011 /- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein (CRP) in the cohort of subjects in the study with elevated CRP....


Reportlinker Adds Global Medical Ultrasound Equipment Industry

February 23, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Feb. 23, 2011 /- announces that a new market research report is available in its catalogue: Global Medical Ultrasound Equipment Industry This report analyzes the worldwide...

Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeich's Genousâ„¢ Stent

February 22, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

HONG KONG, Feb. 22, 2011 /- OrbusNeich today announced that 12-month follow-up data from the e-HEALING ( H ealthy E ndothelial A ccelerated L ining I nhibits N eointimal G rowth) registry published in the February issue of EuroIntervention demonstrated good clinical outcomes with low...

Seal Shield Introduces iPad Keyboard and Case for Healthcare

February 21, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

ORLANDO, Fla., Feb. 21, 2011 /- Seal Shield LLC today announced the new SILVER BLUE™ Bluetooth wireless keyboard and case for the iPad.  The product has been designed specifically for healthcare and addresses infection control concerns over iPad use in hospital settings. The...

LifeWatch Teams With UnitedHealthcare, The Largest Healthcare Insurer In The United States, As A Preferred National Provider Of Cardiac Monitoring Services To Reduce Patient C...

February 20, 2011 10:34 pm | by Bio-Medicine.Org | News | Comments

ROSEMONT, Ill., Feb. 21, 2011 /- LifeWatch AG (SIX Swiss Exchange: LIFE) today announces an initiative with UnitedHealthcare Insurance Company, an affiliate of United-Health Group (NYSE: UNH) that will provide members insured by UnitedHealthcare in-network access to LifeWatch cardiac...

Penn Doctors Certified in New Advanced Heart Failure and Transplant Cardiology Specialty

February 18, 2011 6:33 am | by University Of Pennsylvania | News | Comments

Penn Medicine cardiologists are leaders in a new cardiology subspecialty, Advanced Heart Failure and Transplant Cardiology. Seven of the nine Heart Failure and Transplant doctors at Penn are now certified by the American Board of Internal Medicine (ABIM) in the new Advanced Heart Failure...


Boston Scientific Launches PROMUS® Elementâ„¢ and TAXUS® Elementâ„¢ Stent Systems in India

February 18, 2011 3:36 am | by Boston Scientific | News | Comments

Company's third-generation drug-eluting stents now available in rapidly growing market

MAP Pharmaceuticals Appoints Scott R. Ward as Chairman of the Board of Directors

February 18, 2011 3:36 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Feb. 18, 2011 /- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced the appointment of Scott R. Ward as Chairman of its Board of Directors. Steven A. Elms, the incumbent Chairman and an original venture capital investor in the Company, will step down from the...

Fujifilm's Synapse® Mobility Extends Imaging Reach

February 18, 2011 3:36 am | by Bio-Medicine.Org | News | Comments

STAMFORD, Conn., Feb. 18, 2011 /- FUJIFILM Medical Systems U.S.A., Inc. will be showcasing Synapse® Mobility*, its zero footprint mobile application enabling remote access to Fujifilm's suite of Synapse products from hand-held mobile devices, as well as Macintosh- or Windows-based...

FDA Warns Against Certain Uses of Asthma Drug Terbutaline for Preterm Labor

February 17, 2011 9:35 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., Feb. 17, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration is warning that terbutaline administered by injection or through an infusion pump should not be used in pregnant women for prevention or prolonged (beyond 48-72 hours) treatment of preterm...

New Clinical Study Shows RyMed InVision-Plus® IV Connector Dramatically Reduced Catheter-Related Bloodstream Infections by Over 92%

February 17, 2011 9:35 am | by Bio-Medicine.Org | News | Comments

FRANKLIN, Tenn., Feb. 17, 2011 /- Georgia Health Sciences University, Augusta, GA  exhibited a poster at the recent 11th National Conference on Cancer Nursing Research in Los Angeles, in which their clinical study showed RyMed Technologies ' zero displacement InVision-Plus® IV...


Announcement - Clontech Laboratories, Inc. Releases the Tet-Expressâ„¢ Inducible Expression System

February 17, 2011 4:34 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Feb. 17, 2011 /- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the Tet-Express Inducible Expression System , which provides the quickest and simplest Tet-inducible expression technology yet. At the heart of...

New Mexico Software Initiates Medical Second Opinion Service via Telemedicine for Remote Consultation Review

February 16, 2011 4:34 am | by Bio-Medicine.Org | News | Comments

ALBUQUERQUE, N.M., Feb. 16, 2011 /- New Mexico Software, Inc. (OTC Bulletin Board: NMXC ), a developer of medical IT services and solutions that enable improved and faster communication within the healthcare community, announced today the company will begin providing second opinion...

CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia

February 16, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

KING OF PRUSSIA, Pa. and MONTREAL, Feb. 16, 2011 /- As a means of aiding the World Federation of Hemophilia's (WFH) progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for Progress (GAP) program, CSL Behring has committed to...

Patient-Derived Heart Cells Mimic Disease

February 15, 2011 4:34 am | by Massachusetts Institute of Technology | News | Comments

The cells point to new potential therapies for an inherited heart defect.

Governor Corbett Announces at Least 80 New Jobs in Lehigh Valley with Pharmaceutical Company's Purchase, Renovation of Former Amcor Site

February 15, 2011 4:34 am | by Bio-Medicine.Org | News | Comments

HARRISBURG, Pa., Feb. 15, 2011 /PRNewswire-USNewswire/ -- Governor Tom Corbett today announced that the global pharmaceutical company Daiichi Sankyo Inc. will create more than 80 jobs in the Lehigh Valley with the establishment of its first U.S. manufacturing and packaging operation....

Baxano, Inc. Names George A. Harter, Jr. as Chief Financial Officer

February 15, 2011 4:34 am | by Bio-Medicine.Org | News | Comments

SAN JOSE, Calif., Feb. 15, 2011 /- Baxano, Inc. ( w w w.b a x a no. c om ) today announced the addition of George A. Harter, Jr. to the executive team at Baxano, Inc. As Chief Financial Officer, Mr. Harter will be responsible for Finance, Administration and Human Resources. Mr. Harter...

Boston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine

February 15, 2011 4:34 am | by Bio-Medicine.Org | News | Comments

NATICK, Mass., Feb. 15, 2011 /- Boston Scientific Corporation (NYSE: BSX ) today announced that it has established a $1.7 million endowment to fund the "Donald S. Baim, M.D., '75 Scholarship Fund" for Yale School of Medicine.  This scholarship fund will honor the late interventional...

Nfocus Neuromedical, Inc. Lunaâ„¢ Aneurysm Embolization System Receives CE Mark

February 15, 2011 2:34 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif., Feb. 15, 2011 /- Nfocus Neuromedical, Inc., an innovative medical device company with a focus on the next generation treatment for brain aneurysms, announced today that its Luna™ Aneurysm Embolization System (AES) received CE Mark for the treatment of patients...

Covidien to Launch TurboHawk(TM) Plaque Excision System for Small Vessels

February 15, 2011 2:33 am | by Covidien | News | Comments

New system offers greater efficiency and more consistent performance for physicians MANSFIELD, Mass., Feb 15, 2011 (BUSINESS WIRE) --Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it will launch the TurboHawk(TM) Plaque Excision System for...

New Anti-Clotting Drug Added to Recommendations for Treating Irregular Heartbeat

February 14, 2011 9:35 am | by Bio-Medicine.Org | News | Comments

DALLAS, Feb. 14, 2011 /PRNewswire-USNewswire/ -- The newly approved drug dabigatran is an alternative to warfarin to help prevent dangerous blood clots in patients with atrial fibrillation, according to updated guidelines from the American College of Cardiology, American Heart Association...

ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination

February 14, 2011 9:35 am | by Bio-Medicine.Org | News | Comments

CHICAGO, Feb. 14, 2011 /- Zoledronic acid (sold by Novartis as Zometa, Aclasta, and Reclast) is used to treat Osteoporosis, Tumor Metastasis, and Paget's Disease with sales of $2 billion a year.(1)  It is associated with side effects such as post-dose syndrome and osteonecrosis of...

Dynatronics Announces Fiscal Second Quarter Results

February 14, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

SALT LAKE CITY, Feb. 14, 2011 /- Dynatronics Corporation (Nasdaq: DYNT ) today announced results for its fiscal second quarter ended December 31, 2010. Sales for the quarter ended December 31, 2010, were $8,199,347, compared to $8,501,437 for the quarter ended December 31, 2009. Sales for...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.